Infographic: Here, we share the top 5 oncology news stories we reported this week, including the most recent FDA updates and expert insights on key developments in the field.
Targeted Oncologyreports current advancements in cancer research, including interviews with oncology experts, conference coverage, clinical trial results, and the most recent approvals. Check out our weekly roundup below of the biggest news in oncology that we shared this week.
Follow the links below in our infographic to check out the full story.
This week, the FDA announced 2 new approvals for thetreatment of patients with multiple myelomaas well as fordetectingminimal residual diseasein patients with acute lymphoblastic leukemia or multiple myeloma. A roundup of all the FDA news from September 2018is also now available.
During aTargeted Oncologylive case-based peer perspectives presentation, Rachel Sanborn, MD, director of Thoracic Oncology, Providence Cancer Center, discussed treatment options forpatients with nonsmall cell lung cancer(NSCLC).
In an interview, Javier A. Pinilla-Ibarz, MD, PhD, a senior member of Moffitt Cancer Center, discussed the current treatment landscape for chronic lymphocytic leukemia, as well as some ongoing research in the field.
The top video this week included Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique Hôpitaux de Marseille, France, where he discussed the importance of molecular testing in patients withNSCLC
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More